Metropolitan regions will continue to drive headline economic growth in the US over the coming three to five years. Industry agglomeration, the rising concentration of similar industry-specific companies, will develop supply chains and a region s expertise in certain sectors, attracting further investment and skilled labour. ...Metropolitan regions will continue to drive headline economic growth in the US over the coming three to five years. Industry agglomeration, the rising concentration of similar industry-specific companies, will develop supply chains and a region s expertise in certain sectors, attracting further investment and skilled labour. We are seeing this play out with technology industries in Western metropolitan areas and manufacturing hubs sprouting in the South. ...We are seeing this play out with technology industries in Western metropolitan areas and manufacturing hubs sprouting in the South. In addition, Southern metropolitan areas, including Austin and Miami, will benefit from low operating costs, rising infrastructure spending and expanding transport links that will ease access to both domestic and foreign markets.
...The US has a RRI score of --.- out of --- for Q---. This is unchanged from Q---, and slightly higher than the --.- recorded in Q---. The high RRI score recorded by the US underlines the pharmaceutical market s unassailable status as the most lucrative globally. This is due to unparalleled healthcare access, considerable spending power, a high burden of disease, minimal market access barriers and intense company activity. The key risks to this positive outlook are the increasing influence of pharmacy benefit managers and greater regulation, such as the Branded Prescription Drug Fee. ...This is due to unparalleled healthcare access, considerable spending power, a high burden of disease, minimal market access barriers and intense company activity. The key risks to this positive outlook are the increasing influence of pharmacy benefit managers and greater regulation, such as the Branded Prescription Drug Fee.
...Following the release of ---- financial results for leading drug companies, the expenditure projection for the US pharmaceutical market was revised upwards. We now expect combined sales of prescription drugs and OTC medicines to increase from USD---bn in ---- to USD---bn in ----, representing a compound annual growth rate of -.- . ...
